文献速递前列腺增生与排尿功能障碍

2010至2019年商业保险女性膀胱过度活动症三线治疗的国家趋势

National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010-2019.
PubMed 文献 · Urology · 2022-11-24

利用2010至2019年IBM Marketscan理赔数据识别成年女性膀胱过度活动症患者,分析三线治疗年度使用比例及各类治疗占比变化。共识别3,067,515例患者,其中14,652例启动三线治疗;年度启动三线治疗比例稳定为0.18%(P=0.82),但骶神经调节占比显著下降(P<0.001),膀胱内注射onabotulinumtoxinA(A型肉毒毒素)相应增加,引入后6年内占三线治疗近一半。

要点

  • 商业保险女性膀胱过度活动症患者中三线治疗年度启动率仅0.18%,10年无显著变化(P=0.82)。
  • 骶神经调节占比显著下降(P<0.001),膀胱内注射A型肉毒毒素相应增加。
  • A型肉毒毒素引入后6年内占新启动三线治疗的近一半。

核心结论

  • 非神经源性膀胱过度活动症的三线治疗在商业保险女性中使用率低,新疗法引入导致治疗类型转变而非总体使用增加。

研究设计与样本

  • 基于IBM Marketscan数据库2010至2019年理赔数据的回顾性队列分析,纳入3,067,515例成年女性膀胱过度活动症患者,其中14,652例启动三线治疗。

主要发现

  • 三线治疗年度启动比例稳定为0.18%,10年间无显著变化(P=0.82)。
  • 骶神经调节占比显著下降(P<0.001),膀胱内注射A型肉毒毒素相应增加。
  • A型肉毒毒素引入后6年内占新启动三线治疗的近一半。

关键数值与推荐

  • 三线治疗启动年度比例0.18%(P=0.82)。
  • 骶神经调节占比下降P<0.001。
  • A型肉毒毒素引入后6年内占三线治疗近一半。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether the 2010 introduction of percutaneous tibial nerve stimulation and the 2013 introduction of intradetrusor onabotulinumtoxinA were associated with an increase in overall utilization of third-line treatments. METHODS: Using medical claims data from IBM Marketscan database 2010-2019, diagnosis codes were used to identify adult women with overactive bladder. Procedure codes were used to identify third-line treatments. The annual proportion of patients receiving third-line treatments was calculated, as well as the proportion of each treatment received. These were modeled as a function of treatment year using linear regression; a regression coefficient significantly different from 0 was considered evidence of a significant change in utilization over time. RESULTS: We identified 3,067,515 unique individuals with a diagnosis of overactive bladder, including 14,652 who initiated third-line treatments. The annual percentage of women with overactive bladder who initiated third-line treatment was 0.18% and did not change significantly over 10 years (P = .82). However, the proportion receiving sacral neuromodulation decreased significantly (P <.001), with a compensatory increase in intradetrusor onabotulinumtoxinA. Within 6 years of its introduction, onabotulinumtoxinA accounted for almost half of third-line treatments initiated. CONCLUSION: Overall, third-line therapies for non-neurogenic overactive bladder are utilized infrequently among privately insured women. Over the past decade, the introduction of new treatment options has led to a shift in the type of treatment initiated, rather than to an increase in the overall utilization of third-line therapies.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Edge P, Scioscia NF, Yanek LR, et al. National Trends in Third-Line Treatment for Overactive Bladder Among Commercially Insured Women, 2010-2019. Urology. 2022. PMID: 36436671. doi:10.1016/j.urology.2022.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。